Market closed
Castle Biosciences/$CSTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Castle Biosciences
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Ticker
$CSTL
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
761
Website
CSTL Metrics
BasicAdvanced
$606M
34.29
$0.62
0.98
-
Price and volume
Market cap
$606M
Beta
0.98
52-week high
$33.33
52-week low
$16.97
Average daily volume
398K
Financial strength
Current ratio
7.292
Quick ratio
6.972
Long term debt to equity
5.353
Total debt to equity
5.801
Interest coverage (TTM)
15.03%
Management effectiveness
Return on assets (TTM)
1.10%
Return on equity (TTM)
4.31%
Valuation
Price to earnings (TTM)
34.29
Price to revenue (TTM)
1.778
Price to book
1.33
Price to tangible book (TTM)
1.73
Price to free cash flow (TTM)
16.161
Growth
Revenue change (TTM)
51.09%
Earnings per share change (TTM)
-128.92%
3-year revenue growth (CAGR)
52.25%
3-year earnings per share growth (CAGR)
-20.73%
What the Analysts think about CSTL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.
CSTL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CSTL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CSTL News
AllArticlesVideos
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
GlobeNewsWire·2 weeks ago
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test
GlobeNewsWire·2 weeks ago
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Castle Biosciences stock?
Castle Biosciences (CSTL) has a market cap of $606M as of April 18, 2025.
What is the P/E ratio for Castle Biosciences stock?
The price to earnings (P/E) ratio for Castle Biosciences (CSTL) stock is 34.29 as of April 18, 2025.
Does Castle Biosciences stock pay dividends?
No, Castle Biosciences (CSTL) stock does not pay dividends to its shareholders as of April 18, 2025.
When is the next Castle Biosciences dividend payment date?
Castle Biosciences (CSTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Castle Biosciences?
Castle Biosciences (CSTL) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.